Context to Participate in Upcoming Investor Conferences in April

News Releases
Written By Martin Lehr

Philadelphia, PA, March 19, 2019 – Context Therapeutics, a clinical-stage biotechnology company focused on hormone driven cancers, today announced it will present at the following upcoming investor conferences.

  • Needham and Company 18th Annual Health Care Conference in New York City on Tuesday, April 9, 2019 at 2:30 p.m. ET.

About Context Therapeutics

Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating new medicines to treat hormone-responsive cancers. Context’s lead program is Apristor, an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) breast, endometrial, and ovarian cancers. In addition, Context is advancing CTX-30916, a preclinical progesterone receptor antagonist. For more information on Context, visit www.contexttherapeutics.com.

 

Media Contact
Joanne Jones
Context Therapeutics
jjones@contexttherapeutics.com

or

Investor Contact
Michael Levitan
Solebury Trout
MLevitan@troutgroup.com

 

Martin Lehr
Previous

Context Therapeutics and Memorial Sloan Kettering Cancer Center Announce a Phase 2 Basket Trial for Apristor in PR+ Gynecological Cancers
Next

Context Announces Presentation of New Antiprogestin at the 2019 AACR Annual Meeting